Sun Pharmaceutical Industries (SUNPHARMA) Weekly Analysis
Price & Volume
This week, the stock price saw a slight decrease of -0.27%. The trading range was 1.57%, which is a relatively narrow move. Average daily trading volume decreased by 15.72% compared to the previous week. The stock closed 4.03% above its 50-day moving average and 8.88% above its 200-day moving average.
Technicals
This week, the stock closed at 1930.3, a slight decrease of 0.27% WoW. The price remains above its 20-week and 50-week moving averages (MAs), which are both trending upwards, indicating a positive long-term trend. Momentum is mixed, with the RSI at 61.9, down from last week, suggesting a cooling but still strong upward momentum. Volatility, measured by Bollinger Band width, is at 7.25%, slightly narrower than last week.
Fundamentals
Sun Pharma's recent performance shows a 12.8% YoY revenue increase to ₹14,612.0 in Mar 2026, alongside a 25.8% YoY net profit growth to ₹2,710.0. The operating margin stood at 27.0% for the quarter. While annual growth figures are not available, the quarterly trends indicate positive momentum. The company currently trades at a Price-to-Earnings (PE) ratio of 157.5x and a Price-to-Book (PB) ratio of 20.7x.
News
On Jul 15, Sun Pharma received approval in South Africa for its generic semaglutide, marking its second market for the drug after India. The approval is for adults with Type 2 diabetes as an adjunct to diet and exercise. Separately, the pharmaceutical sector was highlighted as the top performer in 2026 with 13.5% returns, according to TrendMap data. Fund managers expressed positive outlooks on pharmaceuticals, with Bajaj Finserv AMC including it among its top bets. The NSE announced the upcoming launch of futures and options on the Nifty India FPI 150 Index from August 12.
Events
Sun Pharma received approval from South Africa's SAHPRA to manufacture and market a generic semaglutide injection. This approval allows the company to launch the product in the coming days, potentially expanding its market reach for diabetes treatment.
Sun Pharma will announce its Q1 FY2027 results on July 31, 2026, followed by an earnings call at 6:30 pm IST. Shareholders can attend the call to hear management discuss performance.
Sun Pharmaceutical Industries Limited will hold a Board Meeting on July 31, 2026, to approve the unaudited financial results for the quarter ended June 30, 2026. The trading window remains closed until August 2, 2026.
Sun Pharmaceutical Industries Limited announced an investor presentation on July 7, 2026, detailing its financial performance, business operations, R&D, and corporate governance.
Sun Pharmaceutical Industries Limited published newspaper advertisements on July 7, 2026, regarding its 34th Annual General Meeting and e-voting. This informs shareholders about important company proceedings.
Sun Pharma will announce its Q1 FY2027 results on July 31, 2026, followed by an earnings call at 6:30 pm IST. Shareholders can attend the call to hear management discuss performance.
Sun Pharmaceutical Industries Limited will hold a Board Meeting on July 31, 2026, to approve the unaudited financial results for the quarter ended June 30, 2026. The trading window remains closed until August 2, 2026.
Sun Pharmaceutical Industries Limited announced an investor presentation on July 7, 2026, detailing its financial performance, business operations, R&D, and corporate governance.
Sun Pharmaceutical Industries Limited published newspaper advertisements on July 7, 2026, regarding its 34th Annual General Meeting and e-voting. This informs shareholders about important company proceedings.
Weekly Snapshot
Highlights
- The stock experienced a slight price decrease of -0.27% this week, closing at 1930.3, as trading volume declined by 15.72%.
- Sun Pharma received approval in South Africa for its generic semaglutide, a positive development for its diabetes treatment portfolio.
- The pharmaceutical sector was highlighted as the top performer in 2026 with 13.5% returns, indicating positive industry-wide sentiment.
- Technically, the stock remains in an uptrend, trading above its 20-week and 50-week moving averages, though momentum indicators suggest a cooling trend.
- Upcoming Q1 FY2027 results announcement on July 31, 2026, is a key event to monitor for future performance.
What This Means
Sun Pharma's stock saw a minor dip this week amidst lower trading volumes, yet it maintains a positive technical outlook with prices above key moving averages. The company's recent approval for generic semaglutide in South Africa is a notable positive development. The broader pharmaceutical sector's strong performance in 2026 also provides a favorable backdrop. Investors will be closely watching the upcoming Q1 FY2027 earnings announcement for further insights into the company's trajectory.
Latest Quarter Info
For the Mar 2026 period, the company reported revenue of 14,612.0. While revenue shows a positive year-over-year growth of 12.8%, there was a sequential decline of 5.9% quarter-over-quarter. Profitability trends indicate a mixed signal: net profit increased by 25.8% year-over-year, but decreased by 19.8% quarter-over-quarter. The operating margin remained stable at 27.0%. The company's ability to maintain its operating margin despite revenue fluctuations suggests effective cost management. The divergence between year-over-year and quarter-over-quarter performance highlights the need to monitor upcoming periods for sustained trends.